Author | Josep M. Llovet, MD, PhD | OncLive

Author | Josep M. Llovet, MD, PhD

Articles

Dr. Llovet on Efficacy of Namodenoson in Child-Pugh B HCC

August 06, 2019

Video

Josep M. Llovet, MD, discusses a phase II, double-blind, placebo-controlled trial examining the efficacy and safety of namodenoson, an A3 adenosine receptor agonist, as a second-line treatment for patients with Child-Pugh B advanced hepatocellular carcinoma.

Dr. Llovet on REACH Trials With Ramucirumab in HCC

July 17, 2019

Video

Josep M. Llovet, MD, PhD, discusses the REACH and REACH-2 trials, which examined ramucirumab versus placebo in sorafenib-intolerant patients with hepatocellular carcinoma and elevated baseline alpha fetoprotein.

Dr. Llovet Discusses Second-Line Ramucirumab in Advanced HCC

January 19, 2019

Video

Josep M. Llovet, MD, PhD, discusses the results from the phase III REACH-2 study of ramucirumab as a second-line treatment of patients with advanced hepatocellular carcinoma.

Dr. Llovet on Precision Medicine in HCC

October 19, 2018

Video

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential for precision medicine in hepatocellular carcinoma.

x